Document is current
Any future updates will be listed below
-
Authors
Di Marco, Tobias https://orcid.org/0009-0008-8973-2342
Scammell, Thomas E. https://orcid.org/0000-0002-7231-8558
Meinel, Michael
Seboek Kinter, Dalma
Datta, Alexandre N. https://orcid.org/0000-0002-2218-8484
Zammit, Gary https://orcid.org/0000-0001-8332-6687
Dauvilliers, Yves https://orcid.org/0000-0003-0683-6506
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02839200 at ClinicalTrials.govnct03545191 at ClinicalTrials.govDocuments that mention this clinical trial
Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem
https://doi.org/10.1007/s40263-023-01020-9
Documents that mention this clinical trial
Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem
https://doi.org/10.1007/s40263-023-01020-9
What place for daridorexant?
https://doi.org/10.1136/dtb.2023.000037
P4 Daridorexant improves total sleep time (TST) in insomnia patients without altering the proportion of sleep stages
https://doi.org/10.1136/bmjresp-2023-bssconf.15
Meaningful Within-Patient Change on the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ): Analysis of Phase III Clinical Trial Data of Daridorexant
https://doi.org/10.1007/s40290-023-00484-w
Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial
https://doi.org/10.1007/s40266-022-00977-4
-
Funding
Funding for this research was provided by:
Idorsia Pharmaceuticals
- License Information
-
More Information
Article History
Accepted: 21 June 2023
First Online: 21 July 2023
Declarations
:
: These analyses (and the studies on which they are based) were funded by Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland.
: Financial disclosures: YD reports board membership, consultancy, and lecture activity with Idorsia Pharmaceuticals Ltd. TES and AND report consultancy and lecture activity with Idorsia Pharmaceuticals Ltd, Neurocrine, Epilog, Angelini Pharma and Jazz Pharmaceuticals. GZ is an employee of Clinilabs Drug Development Corporation, a company that has received grants from Idorsia Pharmaceuticals Ltd and reports consultancy activity with Idorsia Pharmaceuticals Ltd. TDM and MM are employees of Idorsia Pharmaceuticals Ltd. DSK was an employee of Idorsia Pharmaceuticals Ltd at the time the research was conducted. Non-financial disclosures: none.
: Both the phase II and phase III studies were approved by the appropriate health authority, ethics committee, or institutional review board for each participating site and performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.
: Informed consent was obtained from all individual participants included in the studies.
: Not applicable.
: The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.
: Not applicable.
: All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Michael Meinel, Tobias Di Marco and Yves Dauvilliers. The first draft of the manuscript was written by Tobias Di Marco and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript and agree to be accountable for the work.
